Completed PHASE2 INTERVENTIONAL 2-arm NCT00743938

A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients

Sponsor: Bristol-Myers Squibb

Conditions Non Small Cell Lung Cancer

Interventions BMS-690514 Erlotinib

Updated 8 times since 2017 Last updated: Sep 23, 2015 Started: Mar 31, 2009 Primary completion: Aug 31, 2010 Completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non Small Cell Lung Cancer, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 8 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bahía Blanca, Argentina , Barcelona, Spain , Boston, United States , Buenos Aires, Argentina , Córdoba, Argentina , Detroit, United States , Dunmore, United States , Greenville, United States , Gyeonggi-do, South Korea , La Plata, Argentina and 18 more locations